

1
2
3 Title: Specification of Meningococcal B Vaccine Administration on College Admission
4 Forms
5
6 Introduced by: Brent Oldham for the Medical Student Section
7
8 Original Authors: Evan Brickner, Erica Chang, Nardin Derias, Oluwatoyin Ibiro, Kylee Kus and
9 Manraj Sekhon
10
11 Referred to: Reference Committee D
12
13 House Action: **APPROVED**
14

15
16 Whereas, the United States Advisory Committee on Immunization Practices (ACIP) provided a
17 category B recommendation for both meningococcal serotype B vaccines, as opposed to category A for
18 "routine" recommendation, and
19

20 Whereas, 48 percent of meningococcal diseases with known serogroup in 2015 were of the
21 serogroup B strain (as opposed to A, C, W, or Y)¹, and
22

23 Whereas, meningococcal conjugate vaccines do not include protection against serogroup B
24 meningococcal disease², and
25

26 Whereas, Ball State University, Bucknell University, Indiana University, Indiana State University,
27 New England College, Purdue University, Rivier University, Rose-Hulman Institute of Technology, The
28 College of Idaho, University of Indianapolis, and other universities, require incoming students to receive
29 the MenB vaccine³, and
30

31 Whereas, college students age 18-21 years are at increased risk of contracting serogroup B
32 meningococcal disease compared to non-college-students⁴, and
33

34 Whereas, Indiana State Law added meningitis (including serotype B) to the list of required
35 immunizations for all students matriculating to a residential campus at a state college⁵, and
36

37 Whereas, seven outbreaks of serogroup B meningococcal disease have occurred on college
38 campuses since 2009⁶, and
39

40 Whereas, two vaccines (MenB-FHbp (Trumenba[®]) and MenB-4C (Bexsero[®])) were licensed in 2014
41 and 2015 to protect against serotype B⁷, and
42

43 Whereas, meningococcal disease leads to death in 10 to 15 out of 100 infected individuals despite
44 treatment, and
45

46 Whereas, 10 to 20 out of 100 survivors suffer long term consequences such as hearing loss, brain
47 damage, kidney damage, amputations, nervous system problems, or severe scars from skin grafts, and
48

49 Whereas, 27 colleges in the United States have reported MenB cases since 2008⁸, and
50

51 Whereas, the symptoms of meningitis can be easily confused with the flu and include sudden
52 onset of fever, headache, stiff neck, vomiting, confusion, and light sensitivity, and

53 Whereas, the American Academy of Pediatrics (AAP) recommends the use of MenB-FHbp
54 (Trumenba®) and MenB-4C (Bexsero®) in individuals 10 through 25 years, and

55
56 Whereas, the two vaccines that have been licensed for Meningitis B can be given at the same time
57 as other already mandated vaccines, and

58
59 Whereas, University of California-Santa Barbara (UCSB) requires incoming students to get the
60 meningitis serotype B vaccine, which has been provided by the California and Santa Barbara County
61 departments of Public Health at no cost for UCSB students; therefore be it

62
63 RESOLVED: That MSMS encourage state universities to differentiate between Serotype B from
64 Serotypes A, C, W, and Y on vaccination forms for matriculation onto residential campuses.
65

66 WAYS AND MEANS COMMITTEE FISCAL NOTE: \$5000 or more as this resolutions requires MSMS to reach
67 out to Michigan’s universities with information supporting the required “ask.”

Relevant MSMS Policy: None

Universal Access to Child Immunizations

MSMS supports a policy of universal access to immunizations for all Michigan children. It further supports a strategy whereby the immunizations are purchased by the state at the lowest possible price and made available to all health care providers administering immunizations. (Board-Nov93)

Relevant AMA Policy:

Meningococcal Vaccination for School Children H-60.923

Our AMA supports efforts to require that school children receive meningococcal vaccine per the Advisory Committee on Immunization Practices guidelines.

¹ http://www.immunize.org/askexperts/experts_meningococcal_b.asp

² <https://www.cdc.gov/meningococcal/about/risk-community.html>

³ <https://meningitisbactionproject.org/menbmandatetracker/>

⁴ <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/Mening-02-Meyer-508.pdf>

⁵ <http://iga.in.gov/legislative/2017/bills/house/1069>

⁶ MacNeil J. Considerations for use of serogroup B meningococcal (MenB) vaccines in adolescents. Presented to the Advisory Committee on Immunization Practices. June 24, 2015. <http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-06/mening-03-macneil.pdf>(www.cdc.gov). Accessed October 10, 2015.

⁷ MacNeil J, Rubin L, Temitope F, Ortega-Sanchez I. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2015;64(41):1171-1176.

⁸ <https://meningitisbactionproject.org/menbmandatetracker/> Additional sources: A) <https://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening-serogroup.html> B) <http://studenthealth.sa.ucsb.edu/health-topics/meningitis-b/new-meningitis-b-vaccine/meningitis-b-vaccine-faqs> C) <https://www.cdc.gov/meningococcal/outbreaks/index.html>